Assessing tumor hypoxia by positron emission tomography with Cu-ATSM

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 53, Issue 2, 2009, Pages 193-200

  Holland, J P ^a   Lewis, J S ^a   Dehdashti, F ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Neoplasms; Radionuclide imaging; Tomography, emission computed

Indexed keywords

COPPER 60; COPPER 64; COPPER(II) DIACETYL 2,3 BIS(N4 METHYL 3 THIOSEMICARBAZONATO); RADIOISOTOPE; TRACER; UNCLASSIFIED DRUG; COPPER (II) DIACETYL DI(N(4) METHYLTHIOSEMICARBAZONE); COPPER (II) DIACETYL-DI(N(4)-METHYLTHIOSEMICARBAZONE); DIAGNOSTIC AGENT; ORGANOMETALLIC COMPOUND; THIOSEMICARBAZONE DERIVATIVE;

CANCER THERAPY; CLINICAL ASSESSMENT; DIAGNOSTIC IMAGING; HUMAN; HYPOXIA; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; REVIEW; SOLID TUMOR; TUMOR HYPOXIA; CELL HYPOXIA; NEOPLASM; PATHOLOGY; SCINTISCANNING;

CELL HYPOXIA; HUMANS; NEOPLASMS; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; THIOSEMICARBAZONES;

EID: 69449094645     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Brown JM. The hypoxic cell: a target for selective cancer therapy - eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 1999;59:5863-70.
2. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998;58:1408-16.
3. Höckel M, Knoop C, Schlenger K, Vorndran B, Baussmann E, Mitze M et al. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993;26:45-50. (Pubitemid 23063609)
4. Höckel M, Knoop C, Schlenger K, Vorndran B, Knapstein PG, Vaupel P. Intratumoral pO2 histography as predictive assay in advanced cancer of the uterine cervix. Adv Exp Med Biol 1994;345:445-50. (Pubitemid 24145783)
5. Höckel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509-15. (Pubitemid 26330463)
6. Höckel M, Schlenger K, Höckel S, Aral B, Schaffer U, Vaupel P. Tumor hypoxia in pelvic recurrences of cervical cancer. Int J Cancer 1998;79:365-9.
7. Höckel M, Schlenger K, Knoop C, Vaupel P. Oxygenation of carcinomas of the uterine cervix: evaluation by computerized O2 tension measurements. Cancer Res 1991;51:6098-102.
8. Rofstad EK, Sundfor K, Lyng H, Trope CG. Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. Br J Cancer 2000;83:354-9.
9. Pitson G, Fyles A, Milosevic M, Wylie J, Pintilie M, Hill R. Tumor size and oxygenation are independent predictors of nodal diseases in patients with cervix cancer. Int J Radiat Oncol Biol Phys 2001;51:699-703.
10. Isa AY, Ward TH, West CM, Slevin NJ, Homer JJ. Hypoxia in head and neck cancer. Br J Radiol 2006;79:791-8.
11. Blower PJ, Lewis JS, Zweit J. Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl Med Biol 1996;23:957-80.
12. Anderson CJ, Green MA, Fujibayashi Y. Chemistry of copper radionuclides and radiopharmaceutical products. In: Welch WJ, Redvanly C, editors. Handbook of Radiopharmaceuticals: radiochemistry and applications. West. Sussex, England: John Wiley & Sons, Ltd.; 2003.p.401-22.
13. Anderson CJ, Welch MJ. Radiometal-labeled agents (non-technetium) for diagnostic imaging. Chem Rev 1999;99:2219-34.
14. Novak-Hofer I, Schubiger PA. Copper-67 as a therapeutic nuclide for radioimmunotherapy. Eur J Nucl Med Mol Imaging 2002;29:821-30.
15. Smith SV. Molecular imaging with copper-64. J Inorg Biochem 2004;98:1874-901.
16. Reichert DE, Lewis J, Anderson CJ. Metal complexes as diagnostic tools. Coord Chem Rev 1999;184:3-66.
17. V□vere AL, Lewis JS. Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia. Dalton Trans 2007;:4893-902.
18. McQuade P, McCarthy DW, Welch MJ. Metal radionuclides for PET imaging. In: Valk PE, Bailey DL, Townsend DW, Maisey MN, editors. Positron emission tomography: basic science and clinical practice. London: Springer-Verlag London Ltd.; 2003.p.237-64.
19. McCarthy DW, Bass LA, Cutler PD, Shefer RE, Klinkowstein RE, Herrero P et al. High purity production and potential applications of copper-60 and copper-61. Nucl Med Biol 1999;26:351-8.
20. 64Cu using a biomedical cyclotron. Nucl Med Biol 1997;24:35-43.
21. Obata A, Kasamatsu S, McCarthy DW, Welch MJ, Saji H, Yonekura Y et al. Production of therapeutic quantities of (64)Cu using a 12 MeV cyclotron. Nucl Med Biol 2003;30:535-9.
22. 62Cu-PTSM) in the murine brain; a novel radiopharmaceutical for brain positron emission tomography (PET) imaging. Biol Pharm Bull 1993;16:146-9. (Pubitemid 23129188)
23. 62Cu generator. AJR Am J Roentgenol 2008;190:427-32.
24. Anderson CJ, Connett JM, Schwarz SW, Rocque PA, Guo LW, Philpott GW et al. Copper-64-labeled antibodies for PET imaging. J Nucl Med 1992;33:1685-91.
25. 64Cu-BAT-2IT- 1A3. Cancer Biother Radiopharm 2001;16:483-94. (Pubitemid 34024436)
26. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 1997;38:1155-60. (Pubitemid 27339632)
27. Dearling JLJ, Lewis JS, McCarthy DW, Welch MJ, Blower PJ. Redox-active metal complexes for imaging hypoxic tissues: structure-activity relationships in cooper(II)bis(thiosemicarbazone) complexes. Chem Commun (Camb) 1998;22:2531-2.
28. Dearling JL, Lewis JS, Mullen GE, Welch MJ, Blower PJ. Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships. J Biol Inorg Chem 2002;7:249-59.
29. 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med 1999;40:177-83. (Pubitemid 29044189)
30. Burgman P, O'Donoghue JA, Lewis JS, Welch MJ, Humm JL, Ling CC. Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM. Nucl Med Biol 2005;32:623-30.
31. Lewis JS, Sharp TL, Laforest R, Fujibayashi Y, Welch MJ. Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med 2001;42:655-61. (Pubitemid 32298288)
32. 60Cu-ATSM in cancer of the uterine cervix. J Nucl Med 2008;49:1177-82.
33. Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med 1995;22:265-80.
34. Rajendran JG, Hendrickson KR, Spence AM, Muzi M, Krohn KA, Mankoff DA. Hypoxia imaging-directed radiation treatment planning. Eur J Nucl Med Mol Imaging 2006;33 Suppl 1:44-53.
35. Rajendran JG, Wilson DC, Conrad EU, Peterson LM, Bruckner JD, Rasey JS et al. [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging 2003;30:695-704.
36. Obata A, Yoshimi E, Waki A, Lewis JS, Oyama N, Welch MJ et al. Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent cu-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells. Ann Nucl Med 2001;15:499-504. (Pubitemid 34131947)
37. Maurer RI, Blower PJ, Dilworth JR, Reynolds CA, Zheng Y, Mullen GE. Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone) radiopharmaceuticals. J Med Chem 2002;45:1420-31.
38. Holland JP, Green JC, Dilworth JR. Probing the mechanism of hypoxia selectivity of copper bis(thiosemicarbazonato) complexes: DFT calculation of redox potentials and absolute acidities in solution. Dalton Trans 2006;:783-94.
39. Holland JP, Barnard PJ, Collison D, Dilworth JR, Edge R, Green JC et al. Spectroelectrochemical and computational studies on the mechanism of hypoxia selectivity of copper radiopharmaceuticals. Chemistry 2008;14:5890-907.
40. Okazawa H, Yonekura Y, Fujibayashi Y, Nishizawa S, Magata Y, Ishizu K et al. Clinical application and quantitative evaluation of generator-produced copper-62-PTSM as a brain perfusion tracer for PET. J Nucl Med 1994;35:1910-5. (Pubitemid 24376602)
41. 60/61/62/64Cu-ATSM: a hypoxia imaging agent for PET. Eur J Nucl Med Mol Imaging 2005;32:764-70.
42. Chao KS, Bosch WR, Mutic S, Lewis JS, Dehdashti F, Mintun MA et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2001;49:1171-82.
43. 60Cu- ATSM. Eur J Nucl Med Mol Imaging 2003;30:844-50.
44. 60Cu-ATSM as a predictor of response and survival in patients undergoing neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum 2008;51:1641-8.
45. 60Cu-ATSM: relationship to therapeutic response: a preliminary report. Int J Radiat Oncol Biol Phys 2003;55:1233-8.
46. 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 2008;49:201-5.
47. Tatum JL, Kelloff GJ, Gillies RJ, Arbeit JM, Brown JM, Chao KS et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 2006;82:699-757.
48. Holland JP, Aigbirhio FI, Betts HM, Bonnitcha PD, Burke P, Christlieb M et al. Functionalized bis(thiosemicarbazonato) complexes of zinc and copper: synthetic platforms toward site-specific radiopharmaceuticals. Inorg Chem 2007;46:465-85.
49. 64Cu-complexes for the positron emission tomography imaging of hypoxia. J Med Chem 2008;51:2985-91.
50. Holland JP, Barnard PJ, Bayly SR, Betts HM, Churchill GC, Dilworth JR et al. Synthesis, radiolabeling and confocal fluorescence microscopy of styrene-derivatised bis(thiosemicarbazonato)zinc and -copper complexes. Eur J Inorg Chem 2008;12:1985-93.
51. 64Cu- bis(thiosemicarbazonato)-glucose conjugate for hypoxia imaging. J Nucl Med 2008;49:1862-8.
52. Betts HM, Barnard PJ, Bayly SR, Dilworth JR, Gee AD, Holland JP. Controlled axial coordination: solid-phase synthesis and purification of metallo-radiopharmaceuticals. Angew Chem Int Ed Engl 2008;47:8416-9.